FDA approves Welireg with pembrolizumab for renal cell carcinoma
medicalxpress - The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear ce…
AI Summary: The FDA cleared Welireg (belzutifan) in combination with pembrolizumab for adjuvant treatment of renal cell carcinoma at high risk of recurrence after surgery. The approval expands belzutifan’s indications, offering a new post‑nephrectomy option intended to lower recurrence risk and reflecting regulators’ willingness to endorse targeted therapy combinations in kidney cancer.
Related Stories
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 8 days
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 5 wks
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 1 month
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 2 months
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 5 wks
Datroway secures regulatory approvals in breast cancer across US and EU / 2 months
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Avian Influenza, Pancreatic Cancer, Hospital Operations, Government Policy and look for the RSS link.
StackHealth Time Machine